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Abstract 16 
Vaccinia virus (VACV) is a poxvirus and encodes many proteins that modify the host cell 17 
metabolism or inhibit the host response to infection. For instance, it is known that VACV infection 18 
can activate the MAPK/AP-1 pathway and inhibit activation of the pro-inflammatory transcription 19 
factor NF-κB. Since NF-κB and MAPK/AP-1 share common upstream activators we investigated 20 
whether six different VACV Bcl-2-like NF-κB inhibitors can also influence MAPK/AP-1 activation. 21 
Data presented show that proteins A52, B14 and K7 each contribute to AP-1 activation during 22 
VACV infection and when expressed individually outwith infection. B14 induced the greatest 23 
stimulation of AP-1 and further investigation showed B14 activated mainly the MAPKs ERK and 24 
JNK, and their substrate c-Jun (a component of AP-1). These data indicate that the same viral 25 
protein can have different effects on distinct signalling pathways, in blocking NF-κB activation whilst 26 
leading to MAPK/AP-1 activation. 27 
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 28 
Text 29 
 Viruses subvert cellular biochemistry and inhibit host defense mechanisms to facilitate their 30 
replication and spread (McFadden, 2005). Vaccinia virus (VACV) is the prototypic poxvirus and a 31 
large dsDNA virus that replicates in the cytoplasm. VACV infection triggers the activation of the 32 
MAPKs (mitogen-activated protein kinases) ERK (extracellular signal-regulated kinase) and JNK 33 
(Jun N-terminal kinase) that are subverted to support its replication and spread (De Magalhães et 34 
al., 2001; Andrade et al., 2004; Silva et al., 2006; Pereira et al., 2012). MAPKs are activated by 35 
many different stimuli, such as growth factors, stress and cytokines and can generate several 36 
biological responses within the cell (Kyriakis & Avruch, 2012). One of the most important MAPK 37 
substrates is the transcriptional factor activator protein 1 (AP-1) (Whitmarsh & Davis, 1996). AP-1 is 38 
composed of dimers of basic region-leucine zipper (bZIP) proteins of the Jun (c-Jun, JunB and 39 
JunD), Fos (c-Fos, FosB, Fra1 and Fra2), activating transcription factor (ATF) (ATF2, ATF3/LRF1, 40 
B-ATF, JDP1 and JDP2) and musculoaponeurotic fibrosarcoma (Maf) (c-Maf, MafB, MafA, 41 
MafG/F/K and Nrl) families (Meng & Xia, 2011). Although it is known that VACV triggers AP-1 42 
activation early after infection (De Magalhães et al., 2001) the mechanism by which this occurs is 43 
not understood. 44 
 MAPK pathways interact with other signalling pathways, fine-tuning the appropriate cell 45 
response by integrating different extracellular and intracellular signals. Among those pathways, the 46 
signalling events leading to activation of transcription factor NF-κB share upstream activators with 47 
the MAPKs (Arthur & Ley, 2013). NF-κB is an important factor in inducing the immune response and 48 
VACV encodes at least ten intracellular proteins that inhibit its activation (Sumner et al., 2014). 49 
These proteins are all expressed early during infection and inhibit NF-κB activation at different steps 50 
in the signalling pathway (Smith et al., 2013). In each case studied these proteins also affect 51 
virulence and their deletion causes attenuation (Smith et al., 2013). Six of these inhibitors A46, A49, 52 
A52, B14, K7 and N1, have had their structure solved and are all Bcl-2 family members (Cooray et 53 
al., 2007; Graham et al, 2008; Kalverda et al., 2009; Oda et al., 2009; Fedosyuk et al., 2014; Neidel 54 
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et al., 2015). In this study we have examined if these Bcl-2 family inhibitors of NF-κB also modulate 55 
MAPK/AP-1.  56 
 To determine whether VACV proteins A46, A49, A52, B14, K7 and N1 could interfere with 57 
AP-1 transcriptional activity, AP-1 reporter gene assays were undertaken in HeLa and HEK293T 58 
cells. The AP-1 reporter plasmid (AP-1 Luc), encoding firefly luciferase under the control of 59 
consensus AP-1 binding element repeats [(TGACTAA)7], was a gift of Andrew Bowie (Trinity 60 
College Dublin) and the renilla luciferase control (TK-Ren) plasmid was from Promega. HEK293T 61 
(human embryonic kidney cell line) cells were maintained in Dulbecco’s modified Eagle’s medium 62 
(Gibco) supplemented with 10% heat-treated (56 °C, I h) foetal bovine serum (FBS; Biosera) and 63 
penicillin/streptomycin (P/S) (100 U/ml and 100 μg/ml, respectively). HeLa (human cervical 64 
carcinoma) cells were maintained in minimum essential medium (Gibco) supplemented with 10% 65 
FBS, non-essential amino acids (Sigma) and P/S. Human codon-optimised and Flag-tagged 66 
versions of ORFs A46, A52, B14, K7 and N1, or non-codon optimised A49, were cloned into 67 
pcDNA4.1-TO (Invitrogen) and transfected (100 ng/well) into cells in triplicate with 150 ng/well of 68 
AP-1-Luc and 10 ng/well of TK-Ren plasmids, using TransIT-LT1 Transfection Reagent (Mirus Bio 69 
LLC) according to manufacturer’s instructions. Twenty-four h post-transfection the cells were 70 
stimulated with PMA (phorbol 12-myristate 13-acetate, Sigma) (10 ng/ml) for 24 h, to activate AP-1. 71 
Cells were then harvested in passive lysis buffer (Promega), and the firefly and renilla luciferase 72 
activities were measured using a FLUOstar luminometer (BMG). The firefly luciferase activity in 73 
each sample was normalised to the renilla luciferase activity. Protein expression was confirmed by 74 
immunoblotting using rabbit anti-Flag (Sigma) and mouse anti-α-tubulin primary antibodies 75 
(Millipore), and goat anti-mouse or rabbit IRdye 800CW infrared dye secondary antibodies. 76 
Membranes were imaged using an Odyssey infrared imager (LI-COR Biosciences). 77 
 Fig. 1(a) and (b) show that proteins A52, B14 and K7 in HeLa cells, and proteins A52 and 78 
B14 in HEK cells, caused a significant increase in the levels of AP-1 reporter activity induced by 79 
PMA when compared to empty vector (EV). Furthermore, B14 also induced AP-1 in the absence of 80 
PMA stimulation. In contrast, A49 expression led to a reduction of the AP-1 reporter activity and 81 
proteins A46 and N1 did not alter AP-1 activity when compared to the control. The panels below 82 
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each graph show that the expression levels of the different proteins were similar, except A49 that 83 
was expressed at much lower levels, especially in HeLa cells. Previously, it was reported that A46 84 
inhibits TLR/IL-1-stimulated MAPKs and NF-κB activation, whereas A52 can activate p38 MAPK 85 
and JNK activity, but whether these Bcl-2-like proteins can also induce AP-1 was not demonstrated 86 
(Bowie et al., 2000; Stack et al., 2005; Stack & Bowie, 2012; Maloney et al., 2005; Keating et al., 87 
2007; Stack et al., 2013). B14 was also reported to increase PMA-stimulated AP-1 activity (Chen et 88 
al., 2008). 89 
 Next, the influence of A52, B14 and K7 on AP-1 activation was also investigated during 90 
VACV infection. HeLa cells were transfected with the reporter plasmids and then were either mock-91 
infected or infected with VACV wild-type (WR strain) or mutants lacking gene A46R (Stack et al., 92 
2005), A49R (Mansur et al., 2013), A52R (Harte et al., 2003), B14R (Chen et al. 2006), K7R 93 
(Benfield et al., 2013) or N1L (Bartlett et al., 2002) for 24 h (10 p.f.u. per cell). Infection was 94 
monitored by immunoblotting as described with rabbit anti-C16 (Fahy et al. 2008). VACV infection 95 
induced AP-1 reporter activity when compared to mock-infected cells (Fig. 1c), as demonstrated 96 
previously (De Magalhães et al., 2001). However, the degree of activation was reduced in the 97 
absence of A52, B14 or K7 proteins (Fig. 1c) and enhanced by lack of A49 and these results are 98 
consistent with ectopic expression of these proteins (Fig. 1a, b). Lastly, loss of A46 and N1 did not 99 
affect AP-1 activation during infection. Immunoblotting for VACV protein C16 showed that the 100 
infection was comparable among the different viruses (Fig. 1c). 101 
 Further investigation of AP-1/MAPK activation during VACV infection was undertaken with 102 
protein B14 because it exerted the greatest increase in AP-1 activity. First B14 was shown to 103 
increase AP-1 expression in a dose-dependent manner in both non-stimulated and PMA-stimulated 104 
cells (Fig. 2a). Similarly, AP-1 reporter activity was increased during infection proportionate to the 105 
multiplicity of infection and with time p.i. and vΔB14 induced consistently lower AP-1 activity than 106 
did VACV WR (Fig. 2b). The level of infection in these cells was confirmed by immunoblotting for 107 
the VACV protein C6 (Unterholzner et al., 2011).  108 
 AP-1 is the main substrate of the different MAPK pathways, and so which MAPK was 109 
activated by B14 was investigated next. Firstly, AP-1 reporter activity induced by B14 was 110 
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measured in the presence of specific MAPK inhibitors. HeLa cells were co-transfected with B14 111 
expression vector and the reporter plasmids, and 24 h later, cells were treated with U0126 (inhibitor 112 
of MEK1/2, the upstream activator of ERK, 15 µM), SB203580 (p38α/β MAPK inhibitor, 10 µM), JNK 113 
inhibitor VIII (JNK1/2 inhibitor, 4 µM) or with DMSO, and were stimulated with PMA or left non-114 
stimulated. In the presence of MEK/ERK and JNK inhibitors, the induction of AP-1 by B14 was 115 
decreased significantly (Fig. 3a). In contrast, p38 MAPK inhibition had the opposite effect on the 116 
levels of AP-1 activity induced by B14 alone and no effect on the enhancement of PMA-stimulated 117 
AP-1 activity by B14. This result suggests that B14 is modulating predominantly ERK and JNK to 118 
stimulate AP-1 activity. To confirm this, the phosphorylation levels of the MAPK proteins and the 119 
transcription factor c-Jun were measured when B14 was expressed ectopically or during infection 120 
with VACV-WR and vΔB14 in HeLa cells. Cells were washed twice on ice with ice-cold PBS, and 121 
scrapped into cell lysis buffer (50 mM Tris pH 8, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 1% 122 
Triton X-100, 0.05% NP-40) supplemented with protease and phosphatase inhibitors (Roche). Cell 123 
lysates were subjected to SDS-PAGE and immunoblotting using antibodies from Cell Signaling 124 
Technology: phospho-ERK1/2 (Thr202/Tyr204, #9101), phospho-p38 MAPK (Thr180/Tyr182, 125 
#9211), phospho-JNK1/2 (Thr183/Tyr185, #9251), and phospho-c-Jun (Ser63, #9261). Infection 126 
was confirmed by immunoblotting with mouse mAb against VACV protein D8 (Parkinson & Smith, 127 
1994) and rabbit anti-B14 serum (Chen et al., 2006). 128 
 Even though the inhibition of the MEK/ERK pathway had a significant decrease in AP-1 129 
activation by B14, there was no difference in the levels of activated ERK1/2 in the absence of B14 130 
during the infection (Fig. 3b, lanes 2 and 3). This might be due the existence of other known 131 
proteins encoded by VACV that are able to induce ERK activation, such as VGF and O1 (Andrade 132 
et al., 2004; Schweneker et al., 2012). However, when B14 is expressed alone (Fig. 3b, lanes 4 and 133 
5), an increase of activated ERK1/2 was seen compared to EV and GFP (Fig. 3b, lanes 6 and 7) 134 
even when the amount of B14 plasmid was reduced twofold (Fig. 3b, lane 4). There was a slight 135 
reduction in the phosphorylation of p38 MAPK during infection by vΔB14 (Fig. 3b, lanes 2 and 3) 136 
and a small increase in its phosphorylation in presence of B14 only when 2 μg of plasmid were 137 
used. In contrast, a decrease in JNK1/2 and c-Jun phosphorylation was observed in the absence of 138 
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B14 during infection (Fig. 3b, lanes 2 and 3), and consistent with this observation, there was an 139 
increase in activated JNK1/2 and c-Jun in cells transfected with the B14 plasmid (Fig. 3b, lanes 4 140 
and 5) compared to the controls (Fig. 3b, lanes 6 and 7).   141 
 Taken together, data presented show that VACV proteins A52, B14 and K7, which are all 142 
NF-κB inhibitors, contribute to the activation of AP-1 not only when expressed alone but also during 143 
the infection, while A49 has the opposite effect. The fact that the lack of only one protein resulted in 144 
decreased levels of AP-1 reporter activity in infected cells suggests that these proteins do not have 145 
redundancy in their mechanisms of AP-1 activation. Other viruses also induce AP-1 during infection. 146 
For instance, Epstein–Barr virus (EBV) encodes several proteins that modulate the MAPK pathways 147 
and contribute to AP-1 activation and viral reactivation from latency. EBV protein BRLF1 modulates 148 
all three MAPK pathways (Adamson et al., 2000), while EBV protein BZLF1 activates p38 and JNK 149 
MAPKs (Adamson et al., 2000; Lee et al., 2008) thereby inducing AP-1 activity. More recently, it 150 
was demonstrated that EBV protein BGLF2 also activates AP-1 by regulating the p38 MAPK (Liu & 151 
Cohen, 2016).  152 
 The role of B14 in AP-1 activation was seen clearly during infection by comparing vΔB14 153 
and VACV WR and this correlated with activation of JNK, which is the main kinase responsible for 154 
phosphorylation of the transcription factor c-Jun, the major transcriptional activator of AP-1 (Meng & 155 
Xia, 2011). The removal of B14 did not inhibit JNK activation completely, suggesting the existence 156 
of additional VACV proteins that activate this pathway. Consistent with this, expression of VACV B1 157 
kinase upregulated activated JNK and c-Jun, but that was not demonstrated in the context of 158 
infection (Santos et al., 2006). 159 
 Activation of MEK/ERK during infection by multiple VACV proteins including the Bcl-2 160 
proteins described here, and VGF and protein O1 described previously, aids VACV replication and 161 
suppression of cell death (De Magalhães et al., 2001; Andrade et al., 2004; Postigo et al., 2009). 162 
JNK activation during VACV infection is important for regulation of cytoskeleton reorganisation 163 
required for viral spread (Pereira et al., 2012). Taken together these observations suggest that A52, 164 
possibly via p38 MAPK (Maloney et al., 2005), B14, mainly via JNK/c-Jun, and K7 are increasing 165 
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AP-1 activity to promote VACV multiplication and spread, in addition to their inhibition of NF-κB 166 
activity.  167 
 In summary, these findings show that VACV Bcl-2 family members A52, B14 and K7 168 
modulate AP-1 activity during infection in addition to their known function as inhibitors of activation 169 
of NF-κB and IRF-3 (for K7), illustrating the multi-functional nature of these small alpha-helical 170 
proteins. This may explain in part why removal of these NF-κB inhibitors individually from VACV 171 
gives an in vivo phenotype despite the presence of multiple other inhibitors of this pathway.  172 
 173 
 174 
FIGURES LEGENDS 175 
 176 
Fig. 1 – VACV proteins A52, B14 and K7 induce AP-1. HeLa (a) and HEK (b) cells were co-177 
transfected in triplicate with an AP-1 luciferase reporter, a renilla luciferase internal control and 178 
expression vectors for the proteins shown. Twenty-four h later, the cells were stimulated for 24 h 179 
with PMA or left non-stimulated (NS). (c) AP-1 reporter gene assay in HeLa cells mock-infected or 180 
infected for 24 h with VACV-WR (wild-type) or deletion viruses (10 p.f.u. per cell). Luminescence 181 
was measured and normalised to that of EV non-stimulated or of mock-infected cells to give the fold 182 
induction. Data are shown as the mean SD and are representative of three experiments. Statistical 183 
analysis by unpaired Student’s t test (**p<0.01 ***p<0.001 ****p<0.0001) in comparison to EV 184 
control, either non-stimulated or PMA stimulated (A and B), or VACV-WR (C). The panels below 185 
each graph show protein expression controls by immunoblotting. Molecular masses (in kDa) are 186 
indicated on the left. 187 
 188 
Fig. 2 - B14 stimulates AP-1 in a dose-dependent manner following transfection and 189 
infection. (a) HeLa cells were co-transfected in triplicate with an AP-1 luciferase reporter, a plasmid 190 
expressing renilla luiferase and increasing amounts of B14 vector, or the empty vector (EV). 191 
Twenty-four h later, the cells were stimulated for 24 h with PMA (bottom graph) or left non-192 
stimulated (NS) (top graph). (b) Reporter gene assay in HeLa cells mock-infected or infected for 8 193 
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or 24 h with VACV-WR (wild-type) or B14 deletion viruses, using the indicated multiplicity of 194 
infection (MOI). The luminescence of each sample was measured and normalised to that of EV non-195 
stimulated (a) or mock-infected cells (b) to give the fold induction. Data are shown as the mean SD 196 
and are representative of three experiments. Statistical analysis was by unpaired Student’s t test 197 
(*p<0.05 ****p<0.0001) in comparison to EV control, either non-stimulated or PMA stimulated (A) or 198 
between vΔB14 and VACV-WR (B). The panels below each graph show protein expression controls 199 
by immunoblotting. Molecular masses (in kDa) are indicated on the left.   200 
 201 
Fig. 3 - Contribution of B14 to MAPK activation (a) HeLa cells were co-transfected in triplicate 202 
with an AP-1 luciferase reporter, a renilla luciferase reporter and B14 vectors. After 24 h, cells were 203 
treated with U0126 (MEK/ERK inhibitor), SB203580 (p38 MAPK inhibitor), JNK inhibitor VIII (JNK1/2 204 
inhibitor) or DMSO, and stimulated for 24 h with PMA (10 ng/mL) or left non-stimulated (NS). The 205 
luminescence of each sample was measured and normalised to that of non-stimulated control. Data 206 
are shown as the mean SD and are representative of three experiments. Statistical analysis was by 207 
Student’s t test (***p<0.001). (b) HeLa cells were mock-infected or infected with VACV-WR or 208 
vΔB14 (lanes 1, 2 and 3) for 12 h (5 p.f.u. per cell). In parallel, cells were transfected with the B14, 209 
GFP or empty (EV) vectors or left non-transfected (NT) for 24 h (lanes 4, 5, 6, 7 and 8). Cells were 210 
harvested and lysates were subjected to immunoblotting for the proteins shown. Molecular masses 211 
(in kDa) are indicated on the left. 212 
 213 
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